[go: up one dir, main page]

AU2003222068A1 - Improved methods for achieving expression from alphavirus vectors - Google Patents

Improved methods for achieving expression from alphavirus vectors

Info

Publication number
AU2003222068A1
AU2003222068A1 AU2003222068A AU2003222068A AU2003222068A1 AU 2003222068 A1 AU2003222068 A1 AU 2003222068A1 AU 2003222068 A AU2003222068 A AU 2003222068A AU 2003222068 A AU2003222068 A AU 2003222068A AU 2003222068 A1 AU2003222068 A1 AU 2003222068A1
Authority
AU
Australia
Prior art keywords
improved methods
alphavirus vectors
achieving expression
achieving
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222068A
Other versions
AU2003222068A8 (en
Inventor
Robert E. Johnston
William B. Klimstra
Kate D. Ryman
Jiagang Wang
Laura J. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2003222068A1 publication Critical patent/AU2003222068A1/en
Publication of AU2003222068A8 publication Critical patent/AU2003222068A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003222068A 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors Abandoned AU2003222068A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36789302P 2002-03-25 2002-03-25
US36777602P 2002-03-25 2002-03-25
US60/367,893 2002-03-25
US60/367,776 2002-03-25
PCT/US2003/009121 WO2003083065A2 (en) 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors

Publications (2)

Publication Number Publication Date
AU2003222068A1 true AU2003222068A1 (en) 2003-10-13
AU2003222068A8 AU2003222068A8 (en) 2003-10-13

Family

ID=28678198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222068A Abandoned AU2003222068A1 (en) 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors

Country Status (2)

Country Link
AU (1) AU2003222068A1 (en)
WO (1) WO2003083065A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233061D1 (en) 2001-09-06 2009-09-03 Alphavax Inc ALPHAVIRUS REPLICON VECTOR SYSTEMS
JP5016305B2 (en) 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド Improved alphavirus replicon and helper constructs
DE602004021260D1 (en) 2003-07-11 2009-07-09 Alphavax Inc CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
ES2304880B1 (en) * 2007-04-03 2009-10-27 Proyecto De Biomedicina Cima, S.L. USE OF A MUTED VIRAL VECTOR FOR THE IN VITRO GENERATION OF STABLE CELLULAR LINES.
JP5602624B2 (en) 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド Promoterless cassette for expression of alphavirus structural proteins
GB201310432D0 (en) * 2013-06-12 2013-07-24 Univ St Andrews Virus Production
US10494421B2 (en) 2014-02-10 2019-12-03 Univercells Nv System, apparatus and method for biomolecules production
US12121554B2 (en) 2018-09-14 2024-10-22 Mayo Foundation For Medical Education And Research Materials and methods for treatment with oncolytic viruses and modified CAR T cells
KR20210090650A (en) * 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 Alphavirus neoantigen vectors and interferon inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems

Also Published As

Publication number Publication date
WO2003083065A3 (en) 2004-07-29
AU2003222068A8 (en) 2003-10-13
WO2003083065A2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AU2002334717A1 (en) Improved method for generating an aerosol
AU2003221733A1 (en) Improved raav vectors
AU2003222544A1 (en) Homing process
AU2003286006A1 (en) Cyclotron
AU2002232187A1 (en) Authenticating method
AU2003237038A1 (en) Adaptive rate matching method
AU2003206898A1 (en) Method for rate matching
AU2003260951A1 (en) Region restrictive playback system
AU2003241332A1 (en) Keymat
AU2003301899A1 (en) Member for producing castings
AU2003258070A1 (en) Electrodionization method
AU2003222068A1 (en) Improved methods for achieving expression from alphavirus vectors
AU2003278355A1 (en) Process
AU2003301316A1 (en) Improved immunotherapy
AU2003299732A1 (en) Vectors for inducible rna interference
AU2002950473A0 (en) Expression system
AU2003229646A1 (en) Authentication method
AU2003271883A1 (en) Vector system
AU2003264722A1 (en) Methods
AU2003217765A1 (en) System for hair removal
AU2003253813A1 (en) Method for colpoplasty
AU2003253447A1 (en) Expression vectors
AU2003257434A1 (en) L-amidase from rhizobium huautlense
AU2003263197A1 (en) Process
AU2003278535A1 (en) Histoscreen method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase